Oncovin

(Vincristine)

ApprovedSmall molecule

Vincristine is a chemotherapy drug used to treat various cancers, including leukemia, lymphoma, and some solid tumors, by stopping cancer cells from dividing and growing.[2] Oncovin is currently approved and in use across 62 indications[4].[1]

Oncovin is one of 721 small molecule programs targeting T-cell acute lymphoblastic leukemia. It is currently in Approved.

Indications

444

Total Trials

Active Trials

720

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

T-Cell Acute Lymphoblastic LeukemiaCompleted

LymphomaUnknown status

Acute Lymphoblastic LeukemiaCompleted

TreatmentRecruiting

Immune ThrombocytopeniaActive, not recruiting

RetinoblastomaActive, not recruiting

LenalidomideRecruiting

Diffuse Large B-Cell LymphomaCompleted

MedulloblastomaTerminated

Langerhans Cell HistiocytosisActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Completed

LymphomaApproved

Unknown status

Acute Lymphoblastic LeukemiaApproved

Completed

TreatmentPhase 3

Recruiting

Immune ThrombocytopeniaApproved

Active, not recruiting

RetinoblastomaPhase 2

Active, not recruiting

LenalidomidePhase 2

Recruiting

Diffuse Large B-Cell LymphomaPhase 3

Completed

MedulloblastomaPhase 3

Terminated

Langerhans Cell HistiocytosisPreclinical

Active, not recruiting

Showing 10 of 62 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

95 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Acute Lymphoblastic Leukemia

NCT06207123

Phase 1/2Recruiting

Lenalidomide

NCT04432714

Phase 2Active, not recruiting

Lymphoma

NCT04067037

Q2 2027

Phase 2Active, not recruiting

Ewing Sarcoma

NCT01864109

Phase 3Active, not recruiting

Leukemia

NCT03206671

Recruiting

Real-World Study

NCT05899621

Clinical

Trials by Indication[1]

Lymphoma49 trials

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Unknown status·WWenqi Jiang·Phase 3·NCT02428751·216 enrolled

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Completed· Pfizer logo

Pfizer·Phase 3·NCT01777152·452 enrolled

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03864419·18 enrolled

Show 46 more trials

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Recruiting· Gilead logo

Gilead·Phase 3·NCT05605899·300 enrolled

Stage I/II Nasal NK Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01321008·1 enrolled

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00290498·67 enrolled

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Unknown status·HHunan Cancer Hospital·Phase 2·NCT02918747·100 enrolled

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Enrolling by invitation·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT07258680·114 enrolled

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00809341·27 enrolled

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·N/A·NCT00187122·42 enrolled

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed·UUniversity College, London·Phase 2·NCT01679119·129 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Prospective Study on HIV-related Hodgkin Lymphoma

Unknown status·HHarlachinger Krebshilfe e.V.·Phase 2·NCT01468740·130 enrolled

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193479·51 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00451178·101 enrolled

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Completed· Roche logo

Roche·Phase 3·NCT01332968·1,401 enrolled

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00577993·210 enrolled

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445535·15 enrolled

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Unknown status·RRuijin Hospital·Phase 4·NCT01746992·200 enrolled

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT01415765

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02529852·59 enrolled

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT01004991·14 enrolled

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00274924·100 enrolled

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Terminated·—·Phase 2·NCT00126191·10 enrolled

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT02809573·30 enrolled

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054665·50 enrolled

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT01719835·87 enrolled

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001337·348 enrolled

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00787527·14 enrolled

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Unknown status·TThe Alvin and Lois Lapidus Cancer Institute·Phase 2·NCT00333008·27 enrolled

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Completed·PPolish Lymphoma Research Group·Phase 3·NCT00801281·250 enrolled

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01974440·403 enrolled

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003389·854 enrolled

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Unknown status·PPeking University·Phase 3·NCT03952572·244 enrolled

Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage

Terminated·SSun Yat-sen University·Phase 3·NCT02359162·50 enrolled

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Active, not recruiting·HHenan Cancer Hospital·Phase 2·NCT04067037·60 enrolled

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT04914741·80 enrolled

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Completed·EEmory University·Phase 1/2·NCT00634179·37 enrolled

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Completed· Takeda logo

Takeda·Phase 1/2·NCT01397825·45 enrolled

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02568683·10 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Acute Lymphoblastic Leukemia39 trials

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00526409·40 enrolled

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

Completed·—·Phase 2·NCT00136435·100 enrolled

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00866749·120 enrolled

Show 36 more trials

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting·UUniversity of Washington·Phase 2·NCT05453500·30 enrolled

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

Completed·SSteven E. Coutre·Phase 1·NCT00313079·9 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00198978·377 enrolled

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

Terminated·CClare Twist·Phase 1·NCT00313053·4 enrolled

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00671658·220 enrolled

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting·UUniversity of Chicago·Phase 1/2·NCT06207123·15 enrolled

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05660473·100 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Completed·JJapan Adult Leukemia Study Group·Phase 2·NCT00130195·100 enrolled

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Terminated·EEhab L Atallah·Phase 1·NCT01887587·5 enrolled

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting·MMartin Schrappe·Phase 3·NCT03643276·5,000 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Completed·CChildren's Oncology Group·Phase 1·NCT03792256·12 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)

Completed·GGoethe University·Phase 4·NCT00199069·720 enrolled

Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00905034·37 enrolled

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04752163·17 enrolled

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00890656·90 enrolled

Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia

Completed·IInternational BFM Study Group·Phase 4·NCT00411541·2,600 enrolled

Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00165178·498 enrolled

Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years

Unknown status·PPETHEMA Foundation·N/A·NCT01376427·100 enrolled

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00199186

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Completed·MMassachusetts General Hospital·Phase 2·NCT00973752·30 enrolled

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02404220·30 enrolled

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Unknown status·SSun Yat-sen University·Phase 2·NCT02660762·100 enrolled

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02419469·1 enrolled

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Completed·MMassachusetts General Hospital·Phase 1·NCT02228772·19 enrolled

Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia

Completed·GGoethe University·Phase 4·NCT00199095·40 enrolled

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 2·NCT00131053·120 enrolled

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109837·79 enrolled

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2/3·NCT03117751·790 enrolled

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Recruiting·NNational Hospital Organization Nagoya Medical Center·Phase 2·NCT03286634·60 enrolled

Diffuse Large B-Cell Lymphoma13 trials

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Completed· Takeda logo

Takeda·Phase 2·NCT00931918·206 enrolled

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended·FFavrille·Phase 3·NCT00324831·480 enrolled

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 2·NCT01040871·164 enrolled

Show 10 more trials

Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT01848132·121 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Terminated·LLymphoma Study Association·Phase 3·NCT00135499·138 enrolled

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03274492·1,000 enrolled

Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 1/2·NCT02951728·58 enrolled

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02855359·24 enrolled

The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma

Unknown status·WWuhan University·Phase 3·NCT02449278·120 enrolled

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated·DDeepa Jagadeesh·Phase 1/2·NCT04517435·13 enrolled

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

Withdrawn·AADC Therapeutics S.A.·Phase 1·NCT04974996

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Completed·LLund University Hospital·Phase 1/2·NCT01622439·50 enrolled

Follicular Lymphoma9 trials

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06474481·30 enrolled

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05371093·231 enrolled

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled

Show 6 more trials

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Completed·UUniversity of Liverpool·Phase 3·NCT01303887·680 enrolled

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06704555·20 enrolled

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Completed· GSK logo

GSK·Phase 2·NCT00494780·59 enrolled

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01370694·7 enrolled

Leukemia6 trials

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00968253·24 enrolled

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01000285·18 enrolled

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038610·54 enrolled

Show 3 more trials

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Active, not recruiting·UUniversity Hospital Muenster·Phase 3·NCT03206671·650 enrolled

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT00176462·60 enrolled

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00669877·56 enrolled

51 more indications

Treatment5 trials

A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors

Terminated·—·Phase 2·NCT02110069·4 enrolled

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Unknown status·PPETHEMA Foundation·Phase 4·NCT01358201·100 enrolled

Adult ALL Treatment at Diagnosis

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT00537550

Show 2 more trials

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting·PPETHEMA Foundation··NCT06175702·150 enrolled

Newly Diagnosed4 trials

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Recruiting·OOu Bai, MD/PHD·Phase 2·NCT07493148·50 enrolled

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT04824092·899 enrolled

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Completed·TThe Catholic University of Korea·Phase 2·NCT01004497·51 enrolled

Show 1 more trial

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05887726·30 enrolled

Mantle Cell Lymphoma4 trials

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT00285389·39 enrolled

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT02858804·55 enrolled

Show 1 more trial

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00477412·107 enrolled

Chemotherapy4 trials

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Completed·MM.D. Anderson Cancer Center·N/A·NCT00410488·51 enrolled

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

Terminated·UUniversity of Miami·Phase 2·NCT00450385·57 enrolled

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Terminated·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT01483690·23 enrolled

Show 1 more trial

Reduced Chemotherapy in Low Risk DLBCL

Unknown status·RRuijin Hospital·Phase 4·NCT02752815·290 enrolled

Relapsed or Refractory3 trials

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Terminated·—·Phase 2·NCT02535806·2 enrolled

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Completed· Novartis logo

Novartis·Phase 2·NCT02684058·151 enrolled

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Recruiting·—·Phase 1/2·NCT06709495·63 enrolled

Advanced Stage3 trials

HD21 for Advanced Stages

Active, not recruiting·UUniversity of Cologne·Phase 3·NCT02661503·1,500 enrolled

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Completed·—·Phase 1/2·NCT00379574·49 enrolled

Adult Acute Lymphoblastic Leukemia3 trials

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00853008·100 enrolled

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Completed·RRuijin Hospital·Phase 4·NCT01358253·100 enrolled

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 3·NCT00131027·240 enrolled

Lenalidomide2 trials

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04432714·81 enrolled

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1/2·NCT04423926·91 enrolled

Children2 trials

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02677116·68 enrolled

A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 4·NCT00491946·24 enrolled

Neuroblastoma2 trials

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03786783·42 enrolled

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Completed·—·Phase 2·NCT00165139·20 enrolled

T-cell acute lymphoblastic leukemia2 trials

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03384654·47 enrolled

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06210750

Refractory Solid Tumors2 trials

Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

Suspended·NNational Cancer Institute (NCI)·Phase 1/2·NCT04890093·64 enrolled

Metformin in Children With Relapsed or Refractory Solid Tumors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01528046·26 enrolled

Induction Chemotherapy2 trials

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed·—·Phase 1·NCT01523977·22 enrolled

Efficacy and Safety2 trials

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06387121·53 enrolled

Hematologic Malignancies2 trials

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Recruiting·—·Phase 1·NCT05292664·30 enrolled

Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00718757·4 enrolled

Rhabdomyosarcoma2 trials

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Evolutionary Therapy for Rhabdomyosarcoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04388839·12 enrolled

DLBCL2 trials

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Completed· Roche logo

Roche·Phase 3·NCT02406092·139 enrolled

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03018626·402 enrolled

Multiple Myeloma2 trials

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00201695·12 enrolled

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00441168·30 enrolled

Efficacy2 trials

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209222·360 enrolled

Lymphoblastic Lymphoma2 trials

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Recruiting·UUniversity Hospital Muenster·Phase 3·NCT04043494·683 enrolled

Ewing sarcoma2 trials

Irinotecan and Temozolomide for Ewing Sarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT03359005·60 enrolled

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01864109·83 enrolled

Recurrent or Refractory1 trial

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Completed· Bayer logo

Bayer·Phase 1·NCT02085148·62 enrolled

Lung Cancer1 trial

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Completed·PPharmaMar·Phase 3·NCT02566993·613 enrolled

Advanced Solid Tumors1 trial

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT00960063·4 enrolled

Retinoblastoma1 trial

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

Withdrawn·—·N/A·NCT00980551

Gestational Trophoblastic Tumor1 trial

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Unknown status·WWeiguo Lv·Phase 3·NCT02639650·214 enrolled

Tumour1 trial

Paediatric Hepatic International Tumour Trial

Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT03017326·450 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Medulloblastoma1 trial

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02212574·6 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)

Terminated·—·Phase 1·NCT01463852·11 enrolled

Immune Thrombocytopenia1 trial

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

Completed·—·Phase 4·NCT03229746·40 enrolled

Infants1 trial

Vincristine Pharmacokinetics in Infants

Active, not recruiting·CChildren's Oncology Group··NCT05359237·83 enrolled

Low Grade Glioma1 trial

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00887146·305 enrolled

Recurrent or Refractory Solid Tumors1 trial

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Completed·—·Phase 1·NCT00993044·13 enrolled

Central Nervous System Lymphoma1 trial

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Terminated·EEastern Cooperative Oncology Group·Phase 2·NCT00335140·26 enrolled

Dexamethasone1 trial

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 3·NCT00215943·90 enrolled

Hemangioma1 trial

Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas

Terminated·MMedical College of Wisconsin·Phase 2·NCT00555464·8 enrolled

Hodgkins lymphoma1 trial

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT00284271·65 enrolled

EBV-Positive DLBCL, Nos1 trial

Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04181489·55 enrolled

Wilms tumor1 trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Recruiting·CCentre Oscar Lambret·Phase 1/2·NCT05384821·28 enrolled

CHOP1 trial

Ph II CHOP+Velcade in Mediastinal LBCL

Terminated·—·Phase 2·NCT00361621·3 enrolled

B-cell Malignancies1 trial

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

Completed·—·Phase 1·NCT01760226·4 enrolled

Pediatric Solid Tumors1 trial

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

Completed·—·Phase 1·NCT00786669·13 enrolled

Stem Cell Transplant1 trial

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Adult ALL1 trial

ALL Adult Consortium Trial: Adult ALL Trial

Completed·—·Phase 2·NCT00476190·112 enrolled

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Safety and Efficacy1 trial

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03283202·35 enrolled

Ewing's Sarcoma1 trial

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Induction Therapy1 trial

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00632827·21 enrolled

Randomized1 trial

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Recruiting·FFei Li·Phase 2·NCT06700798·90 enrolled

Unspecified1 trial

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 2·NCT02035137·114 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ONCOVIN

NDA NDA014103

Aug 9, 2012

MARQIBO KIT

NDA NDA202497

Sources

References

[1]
ClinicalTrials.gov — 444 trial records for Vincristine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Oncovin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Vincristine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Vincristine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA202497). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Eli Lilly

Oncovin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Lymphoma49 trials

Acute Lymphoblastic Leukemia39 trials

Diffuse Large B-Cell Lymphoma13 trials

Follicular Lymphoma9 trials

Leukemia6 trials

Treatment5 trials

Newly Diagnosed4 trials

Mantle Cell Lymphoma4 trials

Chemotherapy4 trials

Relapsed or Refractory3 trials

Advanced Stage3 trials

Adult Acute Lymphoblastic Leukemia3 trials

Lenalidomide2 trials

Children2 trials

Neuroblastoma2 trials

T-cell acute lymphoblastic leukemia2 trials

Refractory Solid Tumors2 trials

Induction Chemotherapy2 trials

Efficacy and Safety2 trials

Hematologic Malignancies2 trials

Rhabdomyosarcoma2 trials

DLBCL2 trials

Multiple Myeloma2 trials

Efficacy2 trials

Lymphoblastic Lymphoma2 trials

Ewing sarcoma2 trials

Recurrent or Refractory1 trial

Lung Cancer1 trial

Advanced Solid Tumors1 trial

Retinoblastoma1 trial

Gestational Trophoblastic Tumor1 trial

Tumour1 trial

Real-world Study1 trial

Medulloblastoma1 trial

Chronic Lymphocytic Leukemia1 trial

Immune Thrombocytopenia1 trial

Infants1 trial

Low Grade Glioma1 trial

Recurrent or Refractory Solid Tumors1 trial

Central Nervous System Lymphoma1 trial

Dexamethasone1 trial

Hemangioma1 trial

Hodgkins lymphoma1 trial

EBV-Positive DLBCL, Nos1 trial

Wilms tumor1 trial

CHOP1 trial

B-cell Malignancies1 trial

Pediatric Solid Tumors1 trial

Stem Cell Transplant1 trial

Adult ALL1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Safety and Efficacy1 trial

Ewing's Sarcoma1 trial

Induction Therapy1 trial

Randomized1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News